What is Zosano Pharma Probability of Financial Distress (%)?
Probability of Financial Distress (%) measures the probability that a company will go bankrupt in the upcoming year given its current financial position. A higher ratio indicates a larger probability of bankruptcy for the company, while a lower ratio indicates a healthier fundamental. As of today, Zosano Pharma's Probability of Financial Distress (%) is 0.00%.
Like the Altman Z-Score, the PFD measures a company's bankruptcy risk. However, the main drawback of the Z-score is it does not apply to banks and insurance companies. According to Investopedia, the concept of "working capital" does not apply to banks and insurance companies, as financial institutions do not have typical current assets or current liabilities like inventories or accounts payable.
Competitive Comparison of Zosano Pharma's Probability of Financial Distress (%)
For the Biotechnology subindustry, Zosano Pharma's Probability of Financial Distress (%), along with its competitors' market caps and Probability of Financial Distress (%) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zosano Pharma's Probability of Financial Distress (%) Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zosano Pharma's Probability of Financial Distress (%) distribution charts can be found below:
* The bar in red indicates where Zosano Pharma's Probability of Financial Distress (%) falls into.
Zosano Pharma Probability of Financial Distress (%) Calculation
Probability of Financial Distress (%) (PFD) was developed by John Campbell, Jens Hilscher and Jan Szilagyi in their Search of Distress Risk. It measures the probability that a company will go bankrupt within the next 12 months given its current financial position.
The Probability of Financial Distress (%) was obtained by a logit probability model based on eight explanatory variables. The logit formula to compute the probability of financial distress (LPFD) is given below:
| LPFD | = | -20.12 * NIMTAAVG | + | 1.60 * TLMTA | - | 7.88 * EXRETAVG | + | 1.55 * SIGMA | - | 0.005 * RSIZE | - | 2.27 * CASHMTA | + | 0.070 * MB | - | 0.09 * PRICE | - | 8.87 |
| = | 0.00 |
The Probability of Financial Distress (%) (PFD) was then obtianed by:
| PFD | = | 1 | / | (1 + e^(-LPFD)) | * | 100% |
| = | 0.00% |
The eight explanatory variables are:
1. NIMTAAVG = Net Income to Market Total Assets
*Note that for companies reported quarterly, geometrically declining weighted quarterly Net Income data in latest four quarters are used.
2. TLMTA = Total liabilities to Market Total Assets
3. CASHMTA = Cash to Market Total Assets
For non-financial companies, CASHMTA is measured as:
4. EXRETAVG = Excess Return compared to the S&P 500
EXRETAVG is the weighted excess return compared to the S&P 500 in past 12 month. Geometrically declining weights are imposed on the monthly excess return to reflect lagged information. The weight is halved each quarter.
5. SIGMA = Standard Deviation of Daily Returns
For sigma, we use the annualized standard deviation of a company's returns over the past 92 days (or 63 trading days).
6. RSIZE = Relative Size
| RSIZE | = | log (Market Cap | / | Total Market Cap of S&P 500 companies) |
7. MB = Market to Adjusted Book Equity Ratio
8. PRICE
PRICE is measured as the log of the stock price, capped at log(15).
Zosano Pharma (Zosano Pharma) Business Description
Traded in Other Exchanges
N/A
Address
34790 Ardentech Court, Fremont, CA, USA, 94555
Zosano Pharma Corp is a clinical-stage biopharmaceutical company. It is focused on providing rapid systemic administration of therapeutics and other bioactive molecules to patients using the proprietary transdermal microneedle system. The system is designed to facilitate rapid drug absorption into the bloodstream, which can result in an improved pharmacokinetic profile compared to original dosage forms. The company's operating segment is to develop human pharmaceutical products. Its primary product candidate is Qtrypta (M207) which is the proprietary formulation of zolmitriptan delivered utilizing the system.
Executives
| Christine Matthews |
officer: Chief Financial Officer |
C/O ZOSANO PHAMA CORPORATION, 34790 ARDENTECH COURT, FREMONT CA 94555 |
| Steven Lo |
director, officer: Chief Executive Officer |
C/O CORCEPT THERAPEUTICS, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94010 |
| Donald J Kellerman |
officer: VP, Clinical Dev & Med Affairs |
INSPIRE PHARMACEUTICALS, INC.,, 4222 EMPEROR BLVD., STE. 470, DURHAM NC 27703-8466 |
| Elaine Yang |
director |
C/O ZOSANO PHARMA CORPORATION, 34790 ARDENTECH COURT, FREMONT CA 94555 |
| Kenneth Greathouse |
director |
3260 WHIPPIE ROAD, UNION CITY CA 94587 |
| Hayley Lewis |
officer: See Remarks |
C/O CARBYLAN THERAPEUTICS, INC., 3181 PORTER DRIVE, PALO ALTO CA 94304 |
| Kathy M. Mcgee |
director |
C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355 |
| Linda S Grais |
director |
86 ALEJANDRA AVE, ATHERTON CA 94027 |
| Joseph P Hagan |
director |
3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037 |
| Kleanthis G Xanthopoulos |
director |
9050 CAMINO SANTA FE, SAN DIEGO CA 92121 |
| John Peter Walker |
director |
126 ISABELLA AVE, ATHERTON CA 94027 |
| Aisling Capital Partners Iv, Lp |
10 percent owner |
888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106 |
| Aisling Capital Partners Iv Llc |
10 percent owner |
888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106 |
| Aisling Capital Iv, Lp |
10 percent owner |
888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106 |
| Andrew N Schiff |
10 percent owner |
PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022 |
Zosano Pharma (Zosano Pharma) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ZSANQ has been successfully added to your